Browse Studies — Arctuva

Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study

The goal of this observational study is to collect information on the long-term safety of study participants who received an Allogeneic Chimeric Antigen Recept…

Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Find your next paid study

Improving Patient Outcomes Through a Digital Health Delivered Intervention to Monitor and Manage Symptoms After Chimeric Antigen Receptor T-Cell Therapy

Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study